Escitalopram for the treatment of major depression and anxiety disorders
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Escitalopram is the S-enantiomer of the selective serotonin reuptake inhibitor (SSRI) citalopram, which contains equal amounts of the S- and R-forms in a racemic mixture. Escitalopram is the most selective SSRI, with almost no significant affinity to other tested receptors. It has been demonstrated that it is escitalopram that carries the therapeutic potential of citalopram, and has statistically superior and clinically relevant properties compared with citalopram. Escitalopram is at least as effective in the treatment of depression and anxiety as other SSRIs, as well as venlafaxine, bupropion and duloxetine. Owing to multiple metabolic degrading pathways, the clinically relevant interactions of escitalopram with other drugs are minimal. Compared with other antidepressants, escitalopram is generally better tolerated, its onset of action is relatively fast, and its use may have cost-effectiveness and cost-utility advantages. Escitalopram is an effective first-line option in the management of patients with major depression, including severe forms, and various anxiety disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs)
Hyttel, J. (1994) · International Clinical Psychopharmacology · doi:10.1097/00004850-199403001-00004 · Cited by 492
The Clinical Pharmacokinetics of Escitalopram
Rao, N. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746040-00002 · Cited by 256
Lepola, U. M., Loft, H., & Reines, E. H. (2003) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000074988.54339.7c · Cited by 254
Bielski, R. J., Ventura, D., & Chang, C.-C. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0906 · Cited by 178
Montgomery, S. A., Huusom, A. K. T., & Bothmer, J. (2004) · Neuropsychobiology · doi:10.1159/000078225 · Cited by 168
Lader, M., Stender, K., Bürger, V., & Nil, R. (2004) · Depression and Anxiety · doi:10.1002/da.20014 · Cited by 163
Opbroek, A., Delgado, P. L., Laukes, C., McGahuey, C., Katsanis, J., Moreno, F. A., & Manber, R. (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702002870 · Cited by 147
Escitalopram continuation treatment prevents relapse of depressive episodes
Rapaport, M. H., Bose, A., & Zheng, H. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0107 · Cited by 121
Executive Dysfunction, Heart Disease Burden, and Remission of Geriatric Depression
Alexopoulos, G. S., Kiosses, D. N., Murphy, C., & Heo, M. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300557 · Cited by 117
Montgomery, S. A., Nil, R., Dürr-Pal, N., Loft, H., & Boulenger, J.-P. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1009 · Cited by 115
Baldwin, D. S., Huusom, A. K. T., & Mæhlum, E. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.bp.105.012799 · Cited by 114
Klein, N., Sacher, J., Geiss-Granadia, T., Attarbaschi, T., Mossaheb, N., Lanzenberger, R., Pötzi, C., Holik, A., Spindelegger, C., Asenbaum, S., et al. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0486-0 · Cited by 77
Klein, N., Sacher, J., Geiss-Granadia, T., Mossaheb, N., Attarbaschi, T., Lanzenberger, R., Spindelegger, C., Holik, A., Asenbaum, S., Dudczak, R., et al. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0666-y · Cited by 62
Kornstein, S. G., Bose, A., Li, D., Saikali, K. G., & Gandhi, C. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1115 · Cited by 60
Escitalopram: A Review of its Use in the Management of Anxiety Disorders
Dhillon, S., Scott, L. J., & Plosker, G. L. (2006) · CNS Drugs · doi:10.2165/00023210-200620090-00010 · Cited by 47
Cited by
A meta-analysis of the effect of cognitive bias modification on anxiety and depression
Hallion, L. S., & Ruscio, A. M. (2011) · Psychological Bulletin · doi:10.1037/a0024355 · Cited by 891
Symptom clusters in patients with advanced cancers
Cheung, W. Y., Le, L. W., & Zimmermann, C. (2009) · Supportive Care in Cancer · doi:10.1007/s00520-009-0577-7 · Cited by 166
Zomkowski, A. D. E., Engel, D., Gabilan, N. H., & Rodrigues, A. L. S. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.07.011 · Cited by 94
Jiang, K., Li, L., Xueyi, W., Fang, M., Shi, J., Cao, Q., He, J., Wang, J., Tan, W., & Hu, C. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s120190 · Cited by 18
“Escitalopram, the S-enantiomer of citalopram and the most selective of the SSRIs, has been shown to be efficacious in the treatment of patients with depression and anxiety symptoms.(19,20) According to a meta-analysis of 12 new antidepressants,(21) escitalopram was found to be effective and was the most accepted antid…”
Metadata
- Authors
- Höschl, C., & Švestka, J.
- Venue
- Expert Review of Neurotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2008-04
- Volume
- 8
- Issue
- 4
- Pages
- 537-552
- ISSN
- 1473-7175 (ISSN-L)
- 1744-8360
- OpenAlex
- W2126068921
- Cited by
- 50
- References
- 15
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.